Entest BioMedical and RenovoCyte LLC announced they have treated eight canine patients of a ten dog pilot study utilizing Canine Endometrial Regenerative Cells (CERC) in the treatment of canine osteoarthritis.
Previously, Entest announced the treatment of the first canine patient on November 18, 2011. Since that time Entest’s McDonald Animal Hospital has treated eight dogs in its ten Dog Pilot Study with RenovoCyte. To date, all of the dogs participating in this study have shown dramatic improvement in their mobility and apparent reduction of pain.
Dr. Greg McDonald, Chief Veterinarian at McDonald Animal Hospital, said, “50 million CERC stem cells have been injected intravenously into eight dogs. Each dog selected for this study showed signs of arthritis. Follow-up blood tests, urinalysis and physical exams are now being scheduled for the patients that have already been treated. So far, all these canine patients have shown improvement.”
Entest BioMedical Chairman David Koos stated, “Osteoarthritis is considered one of the most common causes of lameness in dogs, occurring in up to 30% of all dogs. It is caused by a deterioration of joint cartilage, followed by pain and loss of range of motion of the joint. We expect this treatment to relieve these animals from the pain associated with arthritis. This has extraordinary possibilities for dogs and may lead the way for human treatment of arthritic pain.”
The CERC is a “universal donor” stem cell product that does not require matching with the recipient allowing for the generation of standardized products that can be delivered to the office of the veterinarian ready for injection. This is in stark contrast to current stem cell therapies utilized in veterinary applications which require the extraction, manipulation, and subsequent implantation of tissue from the animal being treated.
“We are extremely pleased with our research relationship with Entest BioMedical. This study of canine pets suffering from naturally occurring osteoarthritis is a better test model than laboratory induced disease because it will give us the opportunity for long term follow up of these patients. RenovoCyte sees this study as part of the supporting documentation that will be needed to obtain FDA approval for widespread usage of this therapy,” said Shelly Zacharias, DVM, Director of Veterinary Operations, RenovoCyte, LLC.
A spokesperson for Entest noted the Company is also currently conducting a ten dog safety study on its immune-therapeutic cancer vaccine for dogs, having treated three dogs so far.